日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin or nedaplatin plus tegafur/gimeracil/oteracil as induction chemotherapy regimen for hypopharyngeal cancer

纳米白蛋白结合型紫杉醇联合顺铂或奈达铂联合替加氟/吉美嘧啶/奥替拉西作为下咽癌诱导化疗方案的疗效和安全性

Jiang, Cailing; Liu, Yulan; Mo, Yunyan; Xu, Lieyin; Zhu, Lin; Li, Zhenya; Xu, Shengyuan; Qin, Xi; Wu, Guangteng; Kang, Mafei; He, Xiaosong; Xue, Feng

IDH1 and ATRX mutations synergistically modulate cell proliferation and ferroptosis in glioblastoma cells

IDH1 和 ATRX 突变协同调节胶质母细胞瘤细胞的增殖和铁死亡。

Liu, Siqi; Xiao, Xiangnan; Li, Ang; Ren, Chao; Meng, Bin; Huang, Xiyu; Wang, Xiao; Zhang, Lu; Xu, Mafei

Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review

卡多尼利单抗联合安罗替尼治疗多药耐药性肺大细胞神经内分泌癌的疗效:病例报告及文献综述

Qin, Xi; Liu, Yulan; Zhu, Lin; Xu, Lieyin; Lv, Jinfu; Mo, Yunyan; Kang, Mafei; Xue, Feng

Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study

安罗替尼联合或不联合S-1治疗中国人群晚期肝细胞癌患者的有效性和安全性:一项前瞻性II期研究

Kang, Mafei; Xue, Feng; Xu, Shengyuan; Shi, Jieqiong; Mo, Yunyan

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer

一项前瞻性、开放标签、多中心IV期临床试验,旨在评估洛铂化疗在晚期乳腺癌治疗中的安全性和有效性

Yan, Min; Yuan, Peng; Ouyang, Quchang; Cheng, Ying; Han, Guohui; Wang, Dewei; Ran, Li; Sun, Tao; Zhao, Da; Bai, Yuju; Yang, Shun'e; Wang, Xiaojia; Wu, Rong; Zeng, Xiaohua; Yao, Herui; Ji, Xuening; Jiang, Jun; Hu, Xiaohua; Lin, Haifeng; Zheng, Liping; Zhu, Zhitu; Ge, Wei; Yang, Junlan; Cui, Tongjian; Zhang, Xiaozhi; Lu, Fangyang; Li, Wenhui; Xu, Hongyan; Kang, Mafei; Gong, Ping; Zou, Liqun; Liu, Jiang; Zhang, Hongliang; Yu, Hao; Xu, Binghe

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial

贝伐单抗生物仿制药 LY01008 与贝伐单抗 (Avastin) 作为中国不可切除、转移性或复发性非鳞状非小细胞肺癌患者的一线治疗对比:一项多中心、随机、双盲、 III 期临床试验

Yuankai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Minghong Bi, Xicheng Wang, Jianhua Shi, Ming Zhou, Qian Sun, Guolei Wang, Dongji Chen, Yongqian Shu, Lianke Liu, Zhongliang Guo, Yong Liu, Junquan Yang, Ke Wang, Ke Xiao, Lin Wu, Tienan Yi, Debin Sun, Mafei Kang, Tianjiang Ma, Yimin Mao

Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1

小分子 JQ1 通过 BET 独立的 FOXA1 失活促进前列腺癌侵袭

Leiming Wang, Mafei Xu, Chung-Yang Kao, Sophia Y Tsai, Ming-Jer Tsai

Small-molecule inhibitor targeting orphan nuclear receptor COUP-TFII for prostate cancer treatment

针对孤儿核受体 COUP-TFII 的小分子抑制剂用于治疗前列腺癌

Leiming Wang, Chiang-Min Cheng, Jun Qin, Mafei Xu, Chung-Yang Kao, Jingjing Shi, Erli You, Wanchun Gong, Laura Pedro Rosa, Peter Chase, Louis Scampavia, Franck Madoux, Timothy Spicer, Peter Hodder, H Eric Xu, Sophia Y Tsai, Ming-Jer Tsai

Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction

多巴胺能神经元中 COUP-TFII 表达升高通过线粒体功能障碍加速帕金森病的进展

Chung-Yang Kao, Mafei Xu, Leiming Wang, Shih-Chieh Lin, Hui-Ju Lee, Lita Duraine, Hugo J Bellen, David S Goldstein, Sophia Y Tsai, Ming-Jer Tsai

Nuclear receptors regulate alternative lengthening of telomeres through a novel noncanonical FANCD2 pathway

核受体通过一种新的非经典 FANCD2 通路调节端粒的替代延长

Mafei Xu, Jun Qin, Leiming Wang, Hui-Ju Lee, Chung-Yang Kao, Dan Liu, Zhou Songyang, Junjie Chen, Ming-Jer Tsai, Sophia Y Tsai